Episode Details

Eli Lillys GLP-1 drugs, Mounjaro and Zepbound, have driven significant growth, with Mounjaro sales surging 99% and Zepbound soaring 175% in 2025. These drugs accounted for 56% of the companys revenue and contributed to a 45% overall sales increase. However, the stocks high price-to-earnings ratio of 40 times earnings, compared to the S&P 500s 28 and the average pharma stocks 9, leaves little room for error. While Eli Lilly is investing in new treatments and acquisitions, competition is intensifying, and patents on Mounjaro and Zepbound will eventually expire. Despite strong management, the high valuation makes Eli Lilly a risky investment for long-term buyers.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/043d850af6e19911